Chinese biotech firm Mabworks snags $160m in Series C1, C2 rounds

Chinese biotech firm Mabworks snags $160m in Series C1, C2 rounds

16 April, 2020

Beijing Mabworks Biotech CICC Capital CICC Qide Innovative Biopharmaceutical Equity Investment Fund

Printed by Unregistered user on Tue, 22 Jul 2025 15:17:15 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

China's CICC Capital raises over $229m for biomedicine fund

China's Innocare Pharma plans virtual investor meetings for HK IPO

Read more from Greater China

Venture Capital

Startup funding in Greater China grows 13% in Q2 on Ximalaya’s $2.4b deal

Cannot rely solely on valuation metrics for AI investments: Cathay Innovation